ESLA - Estrella Immunopharma Inc.

https://www.estrellabio.com

Momentum: Bearish

Recent News

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - enGene Holdings ( NASDAQ:ENGN ) , aTyr Pharma ( NASDAQ:ATYR )

Benzinga • 6 months, 4 weeks ago • score: 0.15

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.

52W High

$1.78

52W Low

$0.63

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.37

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.07

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

241.30

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

70.36%

Institutions (25–75% balanced)

1.71%

Shares Outstanding

37,065,600

Float

10,985,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.24

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.69%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0474

0.0484

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025